Table 1 Clinical characteristics of the breast cancer patients based on data from the TCGA
From: GREB1L overexpression is associated with good clinical outcomes in breast cancer
Characteristic | Group | Overall |
|---|---|---|
n | 1083 | |
T stage, n (%) | T1 | 277 (25.6%) |
T2 | 629 (58.2%) | |
T3 | 139 (12.9%) | |
T4 | 35 (3.2%) | |
N stage, n (%) | N0 | 514 (48.3%) |
N1 | 358 (33.6%) | |
N2 | 116 (10.9%) | |
N3 | 76 (7.1%) | |
M stage, n (%) | M0 | 902 (97.8%) |
M1 | 20 (2.2%) | |
Pathologic stage, n (%) | Stage I | 181 (17.1%) |
Stage II | 619 (58.4%) | |
Stage III | 242 (22.8%) | |
Stage IV | 18 (1.7%) | |
Race, n (%) | Asian | 60 (6%) |
Black or African American | 181 (18.2%) | |
White | 753 (75.8%) | |
Age, n (%) |  ≤60 | 601 (55.5%) |
 > 60 | 482 (44.5%) | |
Histological type, n (%) | Infiltrating ductal carcinoma | 772 (79%) |
Infiltrating lobular carcinoma | 205 (21%) | |
PAM50, n (%) | Normal | 40 (3.7%) |
LumA | 562 (51.9%) | |
LumB | 204 (18.8%) | |
Her2 | 82 (7.6%) | |
Basal | 195 (18%) | |
Menopause status, n (%) | Pre | 229 (23.6%) |
Peri | 40 (4.1%) | |
Post | 703 (72.3%) | |
Anatomic neoplasm subgroup, n (%) | Left | 563 (52%) |
Right | 520 (48%) | |
Age, median (IQR) | Â | 58 (48.5, 67) |